JB Chemicals & Pharmaceuticals (JBCPL) has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Tinidazole (for treatment of bacterial infection) 250 mg. and 500 mg. tablets.
The company plans to launch this prescription product in Q4 this year. The company would manufacture these formulations at its state-of-the-art manufacturing facility at Panoli in Gujarat.
The company’s US business has shown good growth in the last two years. The approval for Tinidazole has potential to further strengthen this business. In addition, the company expects approval of few more ANDAs already filed with USFDA. The company also plans to file more ANDAs to support its US business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: